12 scientific teams redefining fast-tracked heart and brain health research related to COVID-19

DALLAS, April 30, 2020 — Less than a month after issuing a rapid response call for scientific research proposals for fast-tracked studies of the effects of COVID-19 on the body’s cardiovascular and cerebrovascular systems, the American Heart Association has awarded $1.2 million in grants to teams at 12 institutions across the U.S. to begin this unprecedented work. Additional funding…

Secondary Impact of the COVID-19 Pandemic on Patients With Heart Failure | Circulation: Heart Failure

The novel coronavirus disease 2019 (COVID-19) pandemic has presented 2 sets of challenges to the heart failure (HF) community. First, we were forced to rapidly establish best practices for the care of patients with HF and COVID-19 and to manage its cardiovascular complications. Although health systems have been immediately and appropriately focused on mitigation, we must prepare for the second…

Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55–65

We read with great interest the article published in European Urology by Vetterlein et al [1], which reported on perioperative morbidity following radical cystectomy. While we would like to commend the authors for discussing the need to precisely assess complications, as this is clearly the first way to improve both short- and long-term results, we sadly recognize that in a leading European…

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

PURPOSE BRCA1 or BRCA2 loss of function results in homologous recombination deficiency (HRD), which is targetable by poly (ADP-ribose) polymerase (PARP) inhibitors and other DNA-damaging agents. In cancers associated with germline BRCA1/2 alterations (BRCA1/2-associated cancers: breast, ovarian, pancreatic, prostate), BRCA1/2 alterations result in HRD and are biomarkers for PARP inhibitor use. In…